Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult participants (male or female), greater than (\>) 18 years of age
Histologically confirmed adenocarcinoma of the colon or the rectum
Primitive lesion is at a distance \>12 centimeter (cm) from the anal margin for participants with primitive rectal tumor
Measurable metastatic disease confined to the liver
Eastern cooperative oncology group (ECOG) performance status 0-1
No previous chemotherapy for metastatic disease or treatment with drugs targeting vascular endothelial growth factor receptor (VEGF) or epidermal growth factor receptor (EGFR)
Adequate bone marrow, liver and renal function
Urine analysis with proteinuria less than (\<) 2+
Use of at least one approved contraceptive method by participants with reproductive potential
Written informed consent from the participants
Surgical criteria for hepatic resection
Adjuvant treatment (either only surgery on primitive tumor or surgery on primitive tumor + adjuvant chemotherapy) must have been concluded greater than or equal to (\>/=) 6 months before enrollment
You may not be if
Presence of extrahepatic metastases
Evidence of lumbo-aortic and celiac lymph nodes involvement
Radiotherapy within 4 weeks before study start
History of inflammatory bowel disease and/or acute/sub-acute bowel occlusion
Presence of serious non-healing wound or ulcer
Evidence of bleeding diathesis or coagulopathy
Clinically significant cardiovascular disease
Uncontrolled hypertension
Current or recent ongoing treatment with anticoagulants
Chronic, daily treatment with high-dose aspirin (\>325 mg/day) or other medications known to predispose to gastrointestinal ulceration
Treatment with any investigational drug within 30 days prior to enrollment
Known allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications
Co-existing malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study. Interval between endoscopic biopsy or colorectal stenting and bevacizumab administration should be evaluated by oncologist/endoscopist
Pregnant or lactating women
Any other disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complication
Participants with known Human immunodeficiency virus (HIV) infection
Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection with concomitant cirrhosis or undergoing active treatment for the same
Participants who are unable or unwilling to comply with the requirements of the protocol and follow-up procedures
Clareo Health | A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
